Phase IIb Protocol 011 Safety Analysis at Week 96: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction

July 18-21, 2021; Virtual
After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: July 20, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) downloadable slides from Drs Joseph Eron, Monica Gandhi, and Patrick Mallon on key advances in HIV treatment from the past year

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI Released: October 4, 2022

Clinical Care Options (CCO) downloadable slides from Drs Gregory Huhn, Colleen Kelley, and Darrell Tan on key advances in HIV prevention from the past year

Gregory Huhn, MD, MPHTM Colleen Kelley, MD, MPH Darrell H. S. Tan, MD, FRCPC, PhD Released: October 4, 2022

Clinical Care Options (CCO) downloadable slides from Drs Katharine Bar and David Margolis on key advances and current directions in HIV cure research

David M. Margolis, MD Released: October 4, 2022

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Julian Falutz, MD, FRCPC Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Released: September 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings